Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2022.0514
Abstract: Importance Patients with breast cancer and brain metastases (BM) have a poor prognosis and high clinical need for novel treatments; however, historically, studies have often excluded these patients. Although the BEACON study did not meet… read more here.
Keywords: treatment etirinotecan; pegol; trial; breast cancer ... See more keywords
C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.
Sign Up to like & getrecommendations! Published in 2020 at "Ophthalmology"
DOI: 10.1016/j.ophtha.2020.08.027
Abstract: PURPOSE The complement pathway may play a key role in the pathogenesis of age-related macular degeneration (AMD). The safety and efficacy of avacincaptad pegol (Zimura®), a C5 inhibitor, was assessed in participants with geographic atrophy… read more here.
Keywords: trial; age related; related macular; pegol ... See more keywords
An open-label randomized controlled trial of DMARD withdrawal in RA patients achieving therapeutic response with certolizumab pegol combined with DMARDs.
Sign Up to like & getrecommendations! Published in 2019 at "Rheumatology"
DOI: 10.1093/rheumatology/kez470
Abstract: OBJECTIVES The objective of this trial was to compare effectiveness of certolizumab pegol added to conventional synthetic DMARDs (csDMARDs) in RA patients, followed by continuing vs discontinuing background csDMARDs after treatment response. METHODS Patients with… read more here.
Keywords: response; certolizumab pegol; patients achieving; pegol ... See more keywords
Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-211388
Abstract: Objectives Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease associated with diffuse immune cell dysfunction. CD40–CD40 ligand (CD40L) interaction activates B cells, antigen-presenting cells and platelets. CD40L blockade might provide an innovative treatment for… read more here.
Keywords: dapirolizumab pegol; systemic lupus; disease; pegol ... See more keywords
The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand disease
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2022007805
Abstract: Key Points The aptamer rondoraptivon pegol improved VWF/FVIII levels, multimer patterns, and thrombocytopenia in type 2B von Willebrand disease. Once weekly subcutaneous injections of rondoraptivon pegol may in the future be used for prophylaxis or… read more here.
Keywords: aptamer rondoraptivon; pegol; vwf fviii; von willebrand ... See more keywords